Compared: Device Regulations in Japan, China, and UK
Regulations for the development of medical devices in Japan, China, and the UK will come under scrutiny
Regulations for the development of medical devices in Japan, China, and the UK will come under scrutiny during a workshop to be held in London on March 20.
The Asia-Pacific Technology Network is organizing the event, with the support of Global Regulatory Services (GRS). Among the speakers will be David Jefferys, MD, Senior Vice-President of Eisai Medical Research and the former Chief Executive and Director of the UK Medical Devices Agency of the Department of Health. He will discuss medical device regulations in Japan, including recent developments and combination products.
By 2017, the global medical device market will be worth around US $434.4 billion, amounting to an annual average growth of 7.1% from 2012, and increasing numbers of devices are hybrids, which combine a device with a medicine, according to the organizers. Pre-filled syringes are an example of a combination product.
“Pharma companies can no longer rely on discovering the next blockbuster, and they are being forced to diversify in order to remain viable; therefore, many are now turning to devices as their next revenue stream. Increasing healthcare costs are helping to drive the growing medical device industry,” they noted in a statement.
For further details on the workshop, contact [email protected]
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
